GlassScriptPhysician profile
Farrell Owen Mendelsohn
NPI 1770548307
$50,647.06
in general payments reported to CMS, 2019-2025
45 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,188 · 2020: $944 · 2021: $15K · 2022: $6,966 · 2023: $12K · 2024: $11K · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Food and Beverage: $2,567 · Travel and Lodging: $1,468 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,575.00 |
| Food and Beverage | $2,567.20 |
| Travel and Lodging | $1,467.66 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $28,356.10 | 2022-2024 | Symplicity G3, Onyx 18, Closurefast |
| Biocardia, INC. | $17,599.75 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $646.55 | 2019-2024 | |
| Amgen INC. | $494.31 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $444.92 | 2020-2025 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $351.69 | 2019-2024 | |
| Pfizer INC. | $350.01 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $252.83 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Janssen Pharmaceuticals, INC | $214.81 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $199.34 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $187.59 | 2019-2025 | Eliquis, Camzyos |
| Preventice Services, LLC | $187.49 | 2020-2021 | |
| Akcea Therapeutics, INC. | $154.44 | 2019-2021 | |
| Astellas Pharma US INC | $126.52 | 2020-2022 | |
| Philips North America LLC | $107.60 | 2019-2020 |
Show all 39 companies
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farrell Mendelsohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.